-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Biologics for the treatment of psoriasis act by inhibiting cytokines important in the pathogenesis of psoriasis, including tumor necrosis factor-alpha, interleukin 12/23, interleukin 17, and interleukin 23
Identify and describe patients with treatment-refractory psoriasis and those who have had a significant response to biological therapy
Patients enrolled in DERMBIO from January 2007 to November 2019 were included
A total of 3280 patients were included, with a mean age of 45.
All told, about 6% of patients treated with biologics had refractory psoriasis and 6% responded well
Source: Loft N, Egeberg A, Rasmussen MK, Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study.
leave a message here